Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma

Sponsor
Duke University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04247971
Collaborator
(none)
60
1
21
2.9

Study Details

Study Description

Brief Summary

The purpose of this study is to gain understanding of mechanisms whereby bariatric surgery modulates pulmonary inflammation and pulmonary microbiome composition and how these changes direct the pathobiology of human obese asthma.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Blood draw
  • Procedure: Sputum collection
  • Procedure: Pulmonary function test

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma
Actual Study Start Date :
Apr 30, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jan 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Obese, early-onset asthmatics

Obese adults (BMI>or= 30) between the ages of 21-60 with an initial asthma diagnosis at <12 years of age

Procedure: Blood draw
23 ml of blood collected

Procedure: Sputum collection
Induced sputum sample collected

Procedure: Pulmonary function test
Pulmonary function testing

Obese, late-onset asthmatics

Obese adults (BMI > or = 30) between the ages of 21-60 with an initial asthma diagnosis at >12 years of age

Procedure: Blood draw
23 ml of blood collected

Procedure: Sputum collection
Induced sputum sample collected

Procedure: Pulmonary function test
Pulmonary function testing

Obese non-asthmatics

Obese adults (BMI > or = 30) between the ages of 21-60 with no asthma diagnosis

Procedure: Blood draw
23 ml of blood collected

Procedure: Sputum collection
Induced sputum sample collected

Procedure: Pulmonary function test
Pulmonary function testing

Outcome Measures

Primary Outcome Measures

  1. Change in leptin levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  2. Change in adiponectin levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  3. Change in IL-8 levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  4. Change in IL-6 levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  5. Change in cystatin-c levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  6. Change in IL-17 levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  7. Change in IL-1beta levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  8. Change in TNF-α levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  9. Change in YKL-40 levels [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  10. Change in lung function as measured by forced expiratory volume [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  11. Change in lung function as measured by forced vital capacity [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  12. Change in lung function as measured by fractional concentration of exhaled nitro oxide [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  13. Change in lung function as measured by FEV1/FVC [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

  14. Change in lung function as measured by forced expiratory flow [Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Asthma Subjects

  • Outpatient adults of either sex 21-60 years of age with an initial asthma diagnosis at < 12 years of age (early-onset) or >12 years of age (late-onset), as defined by the NHLBI NAEPP guidelines (17).

  • Subjects with obesity (BMI ≥ 30 kg/m2).

  • Physician diagnosis of asthma.

  • Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy or duodenal switch) and receiving care within the Duke Health System.

FEV1 within acceptable limits (>45% predicted before and >55% predicted after, bronchodilator administration).

  • Relatively healthy subjects able to undergo sputum induction without complications.

  • Willing and able to give informed consent and adhere to visit/protocol schedules.

  • Read and write in English.

Non-Asthma Control Subjects

  • Outpatient adults of either sex 21-60 years of age.

  • Subjects with obesity (BMI ≥ 30).

  • Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy or duodenal switch) at Duke Regional Hospital and receiving care at the Duke Metabolic and -Weight Loss Surgery Center.

  • Normal lung function.

  • No clinical history of atopy.

  • No significant medical or psychological issues.

  • Healthy subjects able to undergo sputum induction without complications.

  • Willing and able to give informed consent and adhere to visit/protocol schedules.

  • Read and write in English.

Exclusion Criteria:
  • Children < 21 years of age.

  • Inpatient status.

  • Ineligibility or not scheduled for bariatric surgery at the Duke Metabolic and Weight Loss Surgery Center.

  • FEV1 is less than 45% predicted before, or less than 55% predicted after, bronchodilator administration.

  • Upper or lower respiratory tract infection within one month of the study.

  • Use of systemic corticosteroids within four weeks of study.

  • Smoking (tobacco, e-cigarette, vaping or inhaled drugs) history > 5 pack years or smoking or vaping within the previous six months.

  • Significant non-asthma pulmonary disease (stable obstructive sleep apnea is not excluded).

  • An ED visit or inpatient admission for a primary respiratory diagnosis within 60 days of enrollment.

  • Poorly controlled concomitant conditions that pose additional procedure risk as determined by the investigator.

  • All patients on anticoagulants.

  • Uncontrolled sleep apnea.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke University Durham North Carolina United States 27705

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Kunoor Jain-Spangler, MD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT04247971
Other Study ID Numbers:
  • Pro00104326
First Posted:
Jan 30, 2020
Last Update Posted:
Jul 15, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 15, 2022